Please login to the form below

Not currently logged in
Email:
Password:

bioMérieux launches chromID MRSA medium

bioMérieux has launched a new version of chromID MRSA chromogenic medium for the detection of MRSA

bioMérieux has launched a new version of chromID MRSA chromogenic medium for the detection of methicillin resistant Staphylococcus aureus (MRSA), providing a cost-effective solution for rapid routine screening. 

With a maximum read time of 24 hours, compared to 48 hours for the previous version, the new version chromID agar has the potential to increase throughput significantly.

Daniel White, product manager, bioMérieux, said: "Compared to traditional culture media, chromogenic media offer the laboratory an easier method of identifying bacteria through colour differentiation.

"The intensity and specificity of the colours produced make rapid, easy identification of bacterial colonies possible; this new chromID MRSA chromogenic medium will be a great advantage to our customers releasing time and space within the laboratory while at the same time allowing earlier reporting of negatives to facilitate faster clinical decisions."

A ready-to-use medium for the culture, isolation and identification of MRSA, it offers direct identification of MRSA strains within 18 hours, and sensitivity is increased by a further seven per cent when flocked swabs are used for transportation, providing a good synergy with the PREVI Isola automated plate streaker.

The characteristic colours of the colonies – pale blue-green at 18 hours incubation and blue­ green to dark blue at 24 hours incubation – make results easy to read, and the medium has been validated for use with PREVI Isola, VITEK2 and API platforms.

14th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics